Hema Baskarane

1.4K posts

Hema Baskarane banner
Hema Baskarane

Hema Baskarane

@hema_oncologist

MD medicine ( JIPMER), currently pursuing DM Medical oncology in AIIMS New Delhi ..

New Delhi, India Katılım Ocak 2023
936 Takip Edilen301 Takipçiler
Hema Baskarane retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
So much to learn from "negative" trials - a trove of data has poured out from the adjuvant #IMmotion010 study (#atezolizumab v pbo in #localized #kidneycancer), including the #KIM1 story first presented by @AlbigesL & published by @brian_rini in @Annals_Oncology. Now - in @EUplatinum - @VincentWenxinXu describes the evolution of tissue genomics from primary tumor, providing unique perspectives of mechanisms of resistance that are only possible in the context of large, randomized datasets. See below for our tweetorial from last year's @ASCO meeting or follow this link for the paper: pubmed.ncbi.nlm.nih.gov/42036258/
Sumanta K. Pal, MD, FASCO tweet media
Sumanta K. Pal, MD, FASCO@montypal

With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including @VincentWenxinXu @AlbigesL @brian_rini & the tremendous team at @Roche @genentech who saw the value in the extensive correlatives! We looked at ... (1/9)

English
0
22
56
5.3K
Hema Baskarane retweetledi
Prof. Dr. Ahmet Dirican
Prof. Dr. Ahmet Dirican@dr_dirican·
KRAS is no longer “undruggable.” But that’s not the real question. Why does targeting KRAS not lead to the same outcome across cancers? Maybe KRAS is trying to teach us something. Cancer is not just a mutation. It’s a system. How that mutation develops, the microenvironment it lives in, the pathways it interacts with, and how resistance emerges… This is what we need to understand. Because we now know: Targeting a single mutation is not enough. We need to target the network. @OncoDaily @OncBrothers @myESMO @JCO_ASCO @ASCOPost @Dr_R_Kurzrock @tompowles1 @ilyassahinMD nature.com/articles/s4169…
Prof. Dr. Ahmet Dirican tweet media
English
10
56
165
11.7K
Hema Baskarane retweetledi
Tom Powles
Tom Powles@tompowles1·
Ruchi Agarwal #IKCSEU26 @montypal showing microbiome manipulation may enhance efficacy of ipi/nivo in clear cell renal cancer (with CBM588). Randomized phase 3 trials are underway based on this work. This well tolerated intervention is as promising as any other in RCC at present IMO. @OncoAlert @DrChoueiri
Tom Powles tweet mediaTom Powles tweet mediaTom Powles tweet media
English
5
21
67
10.9K
Hema Baskarane retweetledi
Anirban Maitra
Anirban Maitra@Aiims1742·
Happy 25th anniversary to the ORIGINAL Hallmarks of Cancer by Weinberg and Hanahan! @CellCellPress marks the anniversary with a series of reviews: cell.com/cell/fulltext/…
Anirban Maitra tweet media
Raghu Kalluri@rkalluriMDPhD

I had the great pleasure of spending a few hours this afternoon with Bob Weinberg at Whitehead/MIT, catching up on our 25 years of friendship and many conversations about science, life, and society. A legend and a scholar who has deeply shaped our understanding of cancer biology. I am recharged and inspired! @KalluriLab

English
0
16
67
5.3K
Hema Baskarane retweetledi
The ASCO Post
The ASCO Post@ASCOPost·
🏆 Honoring a pioneer in cancer research James P. Allison, PhD, receives the 2026 @AACR Lifetime Achievement Award for discoveries that led to CTLA-4 checkpoint inhibition, transforming #cancercare. Read here: ascopost.com/news/april-202…
The ASCO Post tweet media
English
0
19
90
3.1K
Hema Baskarane retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
It was a short time ago (Dec 2025) that I had the honor of meeting @batraatulonc's amazing oncology team at @aiims_newdelhi! Proud to say that we have organized a terrific meeting to follow-up on initial discussions we had around collaboration. Please join us at @cityofhope on Thursday, May 14 for a vigorous discussion around forging international collaborations with #India. Esteemed guests include @jrgralow (@ASCO CMO), @PrimoLaraMD (@SWOG Co-Chair), @Nilanchali1 (#AIIMSNewDelhi), @DrAmitJoshi_TMC (@TataMemorial), @GsrivastavaMD (@US_FDA) & @neerajaiims (@huntsmancancer). Interesting in attending? DM me!
Sumanta K. Pal, MD, FASCO tweet media
English
3
17
60
7.2K
Hema Baskarane retweetledi
Petros Grivas
Petros Grivas@PGrivasMDPhD·
@urotoday @neerajaiims
UroToday.com@urotoday

Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > bit.ly/49YRtru

QAM
0
2
4
783
Hema Baskarane retweetledi
Tom Powles
Tom Powles@tompowles1·
There are currently 4 global randomized III trials exploring novel ADCs in UC. 2 of them explore different TROP2/TOP1 ADC (like SG which failed for OS in UC) 👉SAC-TMT alone 3rd line 👉D-DXD in combo with platinum 2nd line. IzaBren looks more novel (HER1+3) while the DV/IO study has already been done successfully in China. How many of these will make a difference. @OncoAlert @Annals_Oncology
Tom Powles tweet media
English
0
45
88
7.1K
Hema Baskarane retweetledi
Oscar Tahuahua
Oscar Tahuahua@OscarTahuahua·
🚨 1 in 7 NSCLC patients on first-line immunotherapy will develop severe toxicity And it begins early ➡️14% severe irAEs ➡️~70% within the first 3 months ➡️Median onset 1.4 months Risk ↑ ChT + ICI (HR 2.35) Pre-existing autoimmune disease (HR 1.25) Longer diagnosis to treatment interval (HR 1.50) Risk ↓ Atezolizumab vs pembrolizumab (HR 0.75) Nivolumab (HR 0.91) Lung, blood, GI, these lead (not rare, not late, and not random) The highest risk patients are already defined before treatment and show it within weeks doi.org/10.1038/s41598… @OncoAlert
Oscar Tahuahua tweet media
English
3
26
81
6.7K
Hema Baskarane retweetledi
Tom Powles
Tom Powles@tompowles1·
It looks like KIM1 might be a good biomarker in papillary renal cancer as well as clear cell. Baseline level seem higher in papillary than clear cell and dynamic changes occur with effective therapy. Congrats to @scocmem for this @EUplatinum paper. @OncoAlert @DrChoueiri @montypal @AlbigesL
Sara Coca Membribes@scocmem

✍️Key findings: - Baseline KIM1 was ⬆️in pRCC vs ccRCC - ⬆️baseline KIM1 in ccRCC was linked to shorter OS - Responders showed on-treatment ⤵️KIM1 in both cohorts (−59.2% in ccRCC vs −32% in pRCC) - In ccRCC, on-treatment ⤴️in KIM1 correlated with shorter PFS and OS @OncoAlert

English
3
24
63
7.8K
Hema Baskarane retweetledi
Laura Korin
Laura Korin@laura_korin·
From NOS to a genomic informed category in DLBCL. Will we finally reach the point where biology can guide truly personalized treatment for our patients?
Laura Korin tweet media
English
1
20
73
6.3K
Hema Baskarane retweetledi
Toni Choueiri, MD
Toni Choueiri, MD@DrChoueiri·
Now with ⁦@DrSarcoma⁩ and why 1/10,000 drugs make it to clinic after so many years !
Toni Choueiri, MD tweet media
English
1
5
25
3.1K
Hema Baskarane retweetledi
Ashish M. Kamat, MD, MBBS
Ashish M. Kamat, MD, MBBS@UroDocAsh·
Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC. A milestone reflecting more than a decade of collaborative work by colleagues worldwide einpresswire.com/article/901009… @UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan
English
5
41
107
17.4K
Hema Baskarane retweetledi
Tom Powles
Tom Powles@tompowles1·
A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’ #GUtrendingTopics @OncoAlert
Tom Powles tweet media
English
14
71
190
52.7K
Hema Baskarane retweetledi
Dr.SANTOSH KUMAR CHELLAPURAM MD(AIIMS)DM(AIIMS)
Dr.SANTOSH KUMAR CHELLAPURAM MD(AIIMS)DM(AIIMS)@SChellapuram·
Our Systematic Review of Published Cases of Mycobacterial Infections in Patients With Hairy Cell Leukemia. 🔹 High rates of mycobacterial infections (TB & NTM) 🔹 Often disseminated, even before treatment 🔹 Significant mortality—especially lung invol. academic.oup.com/ofid/article/1…
Dr.SANTOSH KUMAR CHELLAPURAM MD(AIIMS)DM(AIIMS) tweet mediaDr.SANTOSH KUMAR CHELLAPURAM MD(AIIMS)DM(AIIMS) tweet media
English
2
6
25
1.5K

Keşfet

@AlbigesL @brian_rini @Annals_Oncology @EUplatinum @VincentWenxinXu @ASCO @cityofhope @DrMvandenBrink